Plazomicin an antibiotic being developed to fight multidrug-resistant bacterial infections, has met the primary objective of noninferiority compared with meropenem in a phase 3 registration trial among patients with complicated urinary tract infections (cUTIs) and acute pyelonephritis (AP). The EPIC (Evaluating Plazomicin In cUTI) trial was a multinational, randomized, controlled, double-blind study in adults with complicated cUTIs and AP.

Read More